Table 4.

Concordance of data sources on specific DMT use within 5 years in PLM MS patients.^a

	Patient-reported MS medication	MS medication in claims		Agreementb
		Yes	No	Overall	PPA	NPA
Alemtuzumab	Yes	0	0	100.0%	-	100.0%
	No	0	392
Dimethyl fumarate	Yes	47	60	83.4%	90.4%	82.4%
	No	5	280
Fingolimod	Yes	24	27	91.8%	82.8%	92.6%
	No	5	336
Glatiramer acetate	Yes	49	72	74.0%	62.0%	77.0%
	No	30	241
Interferon Beta 1a	Yes	37	86	73.5%	67.3%	74.5%
	No	18	251
Interferon Beta 1b	Yes	11	38	87.2%	47.8%	89.7%
	No	12	331
Metoxantrone	Yes	0	17	95.7%	-	95.7%
	No	0	375
Natalizumab	Yes	15	51	84.2%	57.7%	86.1%
	No	11	315
Peginterferon Beta 1	Yes	0	0	99.7%	0.0%	100.0%
	No	1	391
Teriflunomide	Yes	3	13	94.9%	30.0%	96.6%
	No	7	369

^aDMT use categories in this table reflect claims or patient reported; missing dates for DMT use imputed based on date of medication entry to evaluate use within 5 years.

^bPPA and NPA calculations use IMS claims as reference.